Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Clinical trial NCT01029652 · COMPLETED
Trial details
- NCT number
- NCT01029652
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-01
- Primary completion
- 2010-10-01
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.